# Validose

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/validose

- Industry: Medical Devices & Equipment
- Headquarters: Brooklyn, US
- Website: www.validose.com
- Total disclosed funding: $1.6M
- Latest round: Seed (Dec 16, 2024)
- Investors on record: 2

## About

Validose Inc. specializes in innovative smart-dose technology aimed at improving patient adherence during clinical trials, utilizing real-time data integration for enhanced patient engagement.Validose Inc. was founded in 2017 in Brooklyn, US. The company focuses on developing smart-dose technology to support clinical trial sponsors and research organizations. In December 2024, Validose raised USD 1.6 mn in a funding round led by Peter Bauer’s Family Office, with participation from Interstate Fusion Ventures and 10XBeta. The company has successfully completed one deal to date, highlighting its strategic approach to market engagement. The founder's previous experience details are not publicly available.Validose's core offerings center around its innovative smart-dose technology designed to address patient non-adherence in clinical trials. This technology integrates both objective and subjective data through an intuitive API, providing real-time insights that facilitate proactive engagement with patients. By offering personalized coaching and live interventions, Validose aims to enhance patient behavior and streamline decision-making processes. Their solutions are modular and customizable, allowing for a flexible hardware/software framework that can be deployed standalone or integrated with existing systems. Validose primarily serves clients in the pharmaceutical and biotechnology sectors, with its products marketed across North America and Europe, targeting clinical trial sponsors and research organizations that seek to improve patient adherence and trial outcomes.Validose generates revenue through subscription-based models and direct partnerships with clinical trial sponsors and healthcare organizations. Clients typically engage with Validose to implement its smart-dose technology, which involves an initial setup fee followed by recurring subscription payments for access to the platform and ongoing support services. The company’s revenue structure supports both B2B transactions and direct-to-consumer opportunities, depending on the context of use. While specific pricing details for their products and services are not disclosed, it can be inferred that the revenue model includes tiered subscription plans catering to various client needs, underpinned by their commitment to transforming data-driven patient adherence.In December 2024, Validose Inc. raised USD 1.6 mn in pre-seed funding to accelerate the growth and expansion of the company. The funding will be utilized to enhance current offerings and develop new products aimed at improving patient adherence technology. Validose plans to expand its reach into the European markets, targeting specific countries by 2025. These strategic initiatives are expected to position Validose favorably within the clinical trial landscape.

## Funding rounds

- Seed, Dec 16, 2024, $1.6M — Interstate Fusion Ventures, 10XBeta

## Investors

- Interstate Fusion Ventures (https://capitalatlas.ai/funds/interstate-fusion-ventures) — Seed
- 10XBeta — Seed